Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as President and Chief Executive Officer. She succeeds Ruth McKernan, who continues as a Director on the Board.
Douglas E Williams, Chairman of the Board, said: “We are delighted to welcome Ivana as Draig’s new President and CEO. She is a fantastic addition to the team given her strong track record in growing companies and advancing innovative product candidates for patients in need, particularly in the neuroscience space.”
Ivana joins Draig following her tenure as President and CEO of Vigil Neuroscience, which she founded and led through IPO and clinical development before its acquisition by Sanofi.
She has held senior roles at Ipsen and Teva and currently serves on the boards of Acrivon Therapeutics and Quanterix Corporation.
Ivana said: “I am thrilled to be joining Draig as this exciting stage of its development. In just a short period of time, Draig has established a strong foundation, assembled a team with exceptional talent, and developed a clear path to advance its pipeline of ground-breaking therapies for people with neuropsychiatric disorders.”
Ruth said: “I am extremely proud of the work we have done building Draig, raising $140M at Series A and starting our first phase 2 trial with DT-101. I enthusiastically welcome Ivana, whose exemplary skills will develop the company to deliver transformative medicines for people with neuropsychiatric disorders.”
